E
GSK icon

Entelevest’s GSK GSK Stock Holding History

Entelevest’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,700
Closed -$204K – 150
2026
Q1 		$204K Buy
+3,700
New +$201K 0.2% 107

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM

Entelevest's GSK Position: Q2 2026 in Review

Entelevest sold out of GSK (GSK) in Q2 2026, closing a stake of 3,700 shares — an estimated $204K sold.

Entelevest first reported a position in GSK in Q4 2025 and held it in 2 quarters. The position peaked at $284K in Q4 2025. 296 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Entelevest reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Entelevest sold 3,700 GSK shares in Q2 2026, an estimated $204K.
  • Entelevest first reported a position in GSK in Q4 2025 and held it in 2 quarters.
  • Entelevest's GSK position peaked at $284K in Q4 2025.
  • 296 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Entelevest's 13F filing for Q2 2026, filed 22 Jul 2026.